Viking Therapeutics Inc
VKTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.12B
Close$
$1.47
94% downside
Current Fair Value
94% downsideOvervalued by 94% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.12 Billion |
|---|---|
| Enterprise Value | $2.99 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.19 |
| Beta | 0.65 |
| Outstanding Shares | 115,917,000 |
Return
| Return on Equity | -130.98% |
|---|---|
| Return on Assets | -102.47% |
| Return on Invested Capital | -134.74% |
Valuation & Multiples
| P/E Ratio | -5.24 |
|---|---|
| PEG | -5.5 |
| Price to Sales | - |
| Price to Book Ratio | 8.13 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -5.39 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 29, 2026
EPS Estimate
$-1.23
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
$-1.06
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 34.52% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.18%▼ 64.80% |
|---|---|
| Total Invested | $44.39M▼ 98.51% |
| Investors Holding | 71▼ 400.00% |
ESG Score
No data
About Viking Therapeutics Inc
53 employees
CEO: Brian Lian Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to developing innovative therapies for metabolic and endocrine disorders. Its flagship product candidate, VK2809, is an orally administered, tissue-...